Enalapril (enalapril) tablets 10 mg. №20

Description

Enalapril 10 mg. Storage
active substance: enalapril maleate;

1 tablet contains 2.5 mg or 5 mg, or 10 mg, or 20 mg of enalapril maleate;

Enalapril 10 mg. excipients:

tablets of 2.5 mg and 5 mg: lactose monohydrate, corn starch, talc, sodium bicarbonate, hydroxypropylcellulose, magnesium stearate;

tablets of 10 mg and 20 mg: lactose monohydrate, corn starch, talc, sodium bicarbonate, magnesium stearate, iron oxide red, iron oxide yellow (for tablets of 20 mg).

Enalapril 10 mg. Dosage form
Tablets.

Basic physical and chemical properties:

2.5 mg tablets: white, round, biconvex tablets;

5 mg tablets: white, round, biconvex snap tab tablets with a line on one side;

10 mg tablets: reddish-brown with specks, round, biconvex snap tab tablets with a line on one side;

20 mg tablets: pale orange with specks, round, biconvex snap tab tablets with a line on one side.

Pharmacotherapeutic group
Angiotensin-converting enzyme inhibitors, monocomponent. ATX code C09A A02.

Pharmacological properties

Pharmacodynamics.

Enalapril maleate is a salt of enalapril maleic acid, a derivative of two amino acids – L-alanine and L-proline. Angiotensin-converting enzyme (ACE) is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasopressor substance angiotensin II. After absorption, enalapril is hydrolyzed to enalaprilat, which inhibits ACE inhibitors. Inhibition of ACE leads to a decrease in plasma angiotensin II, resulting in increased renin activity in plasma (due to the elimination of the negative feedback of renin release) and decreased aldosterone secretion.

ACE is identical to kininase II. Thus, enalapril may also block the cleavage of bradykinin, a strong vasodepressor peptide. However, the significance of this phenomenon for the therapeutic effect of enalapril remains unclear.

The mechanism by which enalapril lowers blood pressure is primarily associated with inhibition of renin-angiotensin-aldosterone activity. Enalapril may have an antihypertensive effect even in patients with low-renin hypertension.

Indication
Treatment of arterial hypertension.
Treatment of clinically severe heart failure.
Prevention of clinically severe heart failure in patients with asymptomatic left ventricular dysfunction (ejection fraction <35%).

Contraindication
Hypersensitivity to enalapril, to any of the excipients or to other ACE inhibitors.
Presence of a history of angioneurotic edema associated with previous treatment with ACE inhibitors.
Pregnancy or pregnancy planning (see section “Use during pregnancy or breastfeeding”).
Hereditary or idiopathic angioneurotic edema.
Concomitant use of enalapril with aliskiren-containing drugs in patients with diabetes mellitus or renal impairment (glomerular filtration rate <60 ml / min / 1.73 m2).